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Available online 16 February 2016We previously identiﬁed 34 genes of interest (GOI) in 2006 to aid the oncologists to determine whether post-
mastectomy radiotherapy (PMRT) is indicated for certain patients with breast cancer. At this time, an indepen-
dent cohort of 135 patients having DNA microarray study available from the primary tumor tissue samples
was chosen. Inclusion criteria were 1) mastectomy as the ﬁrst treatment, 2) pathology stages I-III, 3) any
locoregional recurrence (LRR) and 4) no PMRT. After inter-platform data integration of Affymetrix U95 and
U133 Plus 2.0 arrays and quantile normalization, in this paper we used 18 of 34 GOI to divide the mastectomy
patients into high and low risk groups. The 5-year rate of freedom from LRR in the high-risk group was 30%. In
contrast, in the low-risk group it was 99% (p b 0.0001). Multivariate analysis revealed that the 18-gene classiﬁer
independently predicts rates of LRR regardless of nodal status or cancer subtype.
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Prediction1. Introduction
The conventional method in determining the indication for post-
mastectomy radiotherapy (PMRT) is largely based on clinical variables,
such as tumor size, axillary lymph node involvement, hormone receptor
status, age at diagnosis, lymphovascular invasion (LVI), etc. These fac-
tors are known risk factors associated with locoregional recurrence
(LRR). They are, however, imperfect in predicting recurrence (Cheng
et al., 2006a; Taghian et al., 2004). More reliable biological markers
are being sought. Sporadic reports have attempted to show that some
isolated genes could link to LRR (van der Hage et al., 2004; Zellars
et al., 2000).
Patients with four or more axillary lymph-node involvement (N2 or
N3 disease) generallywould be given PMRT (Recht et al., 2001). Howev-
er, there is controversy concerning patientswith 1–3 positive nodes (N1
disease), even thoughNCCNguidelines “strongly consider” giving PMRT
based on large meta-analyses from many randomized control trialsOncology, Koo Foundation Sun
trict, Taipei, Taiwan.
rng@kfsyscc.org (C.-F. Horng),
uang), MHTSOU@kfsyscc.org
kfsyscc.org (B.-L. Yu),
A.T. Huang).
. This is an open access article under(Clarke et al., 2005; Early Breast Cancer Trialists' Collaborative, 2002;
EBCTCG et al., 2014). In fact, the likelihood of LRR after 10 years in
node negative patients is reported to be approximately 2–8%, N1
patients 20%, and N2 patients 32% (Clarke et al., 2005; EBCTCG et al.,
2014). Therefore, if we rely only on clinical parameters, around
70–80% of the node-positive patients could potentially undergo
overtreatment, whereas those at risk in node negative disease could
potentially be undertreated.
Recent progress in genomic analyses for evaluating tumor biology
show signiﬁcant agreement in the outcome predictions for individual
patients who are probably sharing a common set of biologic pheno-
types. This opened a new possibility to improve risk stratiﬁcation that
led to more personalized prognostication for breast cancer patients
(Fan et al., 2006; Sorlie et al., 2001). Studies from gene expression pro-
ﬁling have shown a greater capability of determining prognosis and
predicting response to adjuvant chemotherapy in Tamoxifen-treated
patients (Paik et al., 2004a, 2004b, 2006). In 2006, we reported 34 and
258 gene sets that could partition the LRR high risk patients from the
LRR low risk patients after mastectomy. The low risk group determined
by the gene expression proﬁling had a 3-year LRR rate of less than 3%,
and the high risk group had an LRR rate of more than 50% (Cheng
et al., 2006b). In this study, we evaluated 34 genes of interest (GOI) in
the prediction of LRR using a completely different patient populationthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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PMRT could be avoided.2. Material and Methods
2.1. Patients
Patients with invasive breast cancer were collected in a study of
“Precision Medicine in Oncology for Taiwan” at Koo Foundation Sun Yat-
Sen Cancer Center in an attempt to develop a new taxonomy for breast
cancer, which was approved by the Bio-bank Ethics Committee and In-
stitutional Review Board. All 135 patients eligible for this study had had
the approval of these two review bodies.
The present study focused on validating the gene expression proﬁles
that are related to LRR following mastectomy. Patients are eligible if
they satisﬁed the inclusion criteria set in our 2006 study: i.e. 1) mastec-
tomy as ﬁrst treatment, 2) frozen fresh tissue available, 3) pathology
stages I-III disease, 4) any LRR, 5) no PMRT, 6) minimal follow up of 2
years, and 7) an informed consent (Fig. 1). One hundred thirty ﬁve
(135) patients were enrolled in this study.
We hypothesize that if the 18-gene classiﬁer were capable of identi-
fying locally aggressiveness of tumor biology and predicting LRR forFig. 1. Diagram to develop gene expression proﬁling that predicts locoregional recurrence in m
similar, or greater ability to partition the low and high risk patients after mastectomy.mastectomy patients, it would also be effective to predict LRR after
BCS even though they had adjuvant radiotherapy. We then used the
breast-conserving surgery (BCS) patients who were treated in the
same study period (n = 87) as a conﬁrmatory cohort.
2.2. Samples and Microarray Analysis
A total of 135 frozen tissue samples came from surgical specimens of
the primary tumors taken frompatients prior to any treatment between
2005 and 2012. Tumor RNA was extracted from primary tumor tissues
with Trizol (Invitrogen, Carlsbad, CA) and puriﬁed with the RNeasy
Mini Kit (Qiagen, Valencia, CA), and assessed for quality with an Agilent
2100 Bioanalyzer. According to the Affymetrix protocol, hybridization
targets were prepared from the total RNA and hybridized to U133 Plus
2.0 arrays. The details of the study method have been reported previ-
ously by investigators of our institution (Kao et al., 2011).
2.3. Statistical Analysis to Identify Gene Expression Proﬁles of LRR
In this study, the microarray platform was shifted from Affymetrix
U95 to U133 Plus 2.0 array (Fig. 1). There were 30 of 34 GOI identiﬁed
in this new platform, where they were distributed in 84 probes. Anastectomy patients. The genes of interest (GOI) reduced from 258 to 18 and maintained a
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platform IDs to Unigene and RefSeq IDs using identiﬁer ﬁles provided
by Affymetrix. A mean shift quantile normalization of 135 patients
was done in the new platform to make sure all samples from both
platforms were comparable (Fig. 1) (Sohal et al., 2008).
The statistical methods in our previous study were complicated: i.e.
unsupervised clustering, logistic regression analysis, classiﬁcation trees
and Bayesian statistical methods, leave-one-out cross validation, and
Pearson correlation coefﬁcient. In brief, we used the concept of
‘metagene’ where each ‘metagene’ represented a key common pattern
of expression of the genes in a cluster based on k-means clustering
(Huang et al., 2003). Subsequently, we generated classiﬁcation trees
and used Bayesian statistical methods to explore multiple metagenes
for optimal prediction. Finally 34 GOI were identiﬁed from 258 GOI
using Pearson correlation coefﬁcient (b0.3 or N0.3) (Cheng et al.,
2006b).
In the current study, we selected the top 18 of 34 genes with highest
correlation to partition mastectomy patients into the high and low risk
groups and perform a cross validation of this 18-gene panel in our 2006
dataset (Table 2). We then optimize the 18-gene expression proﬁling in
prediction of LRR and generate the 18-gene scoring algorithm according
to the multivariate analysis (Fig. 2). The scoring algorithm is as follows:
18-gene scores = 4 × TRPV6 + 3 × DDX39 + 8 × BUB1B + CCR1 +
STIL + 3 × BLM + 11 × C16ORF7 + 4 × PIM1 + TPX2 + 2 × PTI1 +
2 × TCF3 + CCNB1 + DTX2 + 2 × ENSA + 5 × RCHY1 +
4 × NFATC2IP + OBSL1 + 2 × MMP15.
2.4. Statistical Considerations
Cox proportional hazards regression models were used to assess the
prognostic signiﬁcance of the following risk factors: age at diagnosis,
primary tumor size, number of involved axillary lymph nodes, nuclear
grade, LVI, ER status, and the 18-gene score. Duration of locoregional
control was calculated from the ﬁrst day of treatment until the day of
chest wall or regional nodal recurrence, or the last follow-up. LRR and
distant metastasis that occurred simultaneously were counted as both.
LRR that occurred after distant metastasis was censored. The LRR-freeFig. 2.Anunsupervised cluster analysis of 18 genes and supervised clustering in 135patients acc
without recurrence. Patients with locoregional recurrence (LRR) are colored as blue ( ), both LR
red ( ), and disease free patients are colored as yellow ( ) in the bottom of the heatmap.survival rates were calculated according to the Kaplan and Meier
method (Kaplan and Meier, 1958). The log-rank test and chi-squared
test were used to assess the statistical signiﬁcance of the differences in
LRR between patient subsets.
3. Results
The median follow-up of 135 patients was 65.1 months (ranging
from 4.3–149.7 months). The details of patients' characteristics and
treatment information are shown in Table 1. The majority of patients
in this study were in the T2 or T3 disease groups (56%, n = 75), 68%
(92) inN0disease, and 77% (104) over the age of 40. Adjuvant hormonal
therapywas given to 60% (81/135) of the patients, and chemotherapy to
79% (106) of the patients. There were 11 patients with LRR, 15 patients
with distant recurrence and 10 patients with both locoregional and dis-
tant recurrences. Factors associated with any recurrence were the pri-
mary tumor stage and nodal involvement (Table 1). The study
samples compared with the dataset in 2006 were earlier stage and
less common of prominent LVI (Supplement Table 1).
Using the Cox regression model, 30 GOI with the new reference
distribution of gene-expression levels, it was possible to distinguish
mastectomy patients into the LRR low/high risk groups for the data
set published in 2006 (Table 2) (Cheng et al., 2006b). This 30-gene
panel could also distinguish the current data set (n = 135) into the
low/high risk groups if each gene were given equal weighting for the
scoring algorithm (Table 2). Patients classiﬁed as high risk had an LRR
rate of 53%, whereas the low risk patients had an LRR rate of 3%. We
used the top 18 genes with highest correlation to optimize our ﬁnal
predictionmodel. Again, if we assigned each genewith equal weighting
of scoring, the 18 genes were capable of partitioning patients into the
low and high risk groups among samples between 2006 and 2014
(Table 2, p b 0.0001).
The signiﬁcance of 18 GOI related to LRR in the study patients using
univariate analysis was shown in Supplement Table 2. Among them,
TRPV6, C16ORF7, and RCHY1 were independent genes by multivariate
analysis. The hazard ratios of 18 genes by multivariate analysis in the
Cox model were composed of the prediction score (18-gene score).ording to the 18-gene scores revealed distinct gene expression proﬁles in patientswith and
R and distantmetastasis are colored as purple ( ), distantmetastasis patients are colored as
Table 1
Patient characteristics and treatment information (N= 135).
Characteristics No relapse (N = 99) Any relapsea (N = 36) p-Value
Median age (range) 50 (25–83) 49 (26–80) 0.0699
Age
≤40 19 (61.3) 12 (38.7) 0.2183
41–50 31 (75.6) 10 (24.4)
N50 49 (77.8) 14 (22.2)
T stage
T1 52 (86.7) 8 (13.3) 0.0017
T2–T3 47 (62.7) 28 (37.3)
Axillary node positive
N0 80 (87.0) 12 (13.0) b0.0001
N1 18 (51.4) 17 (48.6)
≥N2 1 (12.5) 7 (87.5)
Nuclear grade
I/II 53 (79.1) 14 (20.9) 0.1323
III 46 (67.7) 22 (32.4)
Lymphovascular invasion
Absent 45 (79.0) 12 (21.1) 0.1197
Focal 39 (75.0) 13 (25.0)
Prominent 15 (57.7) 11 (42.3)
Estrogen-receptor status
Negative 32 (66.7) 16 (33.3) 0.1932
Positive 67 (77.0) 20 (23.0)
Progesterone-receptor status
Negative 50 (69.4) 22 (30.6) 0.2747
Positive 49 (77.8) 14 (22.2)
HER2 overexpression
Negative 63 (71.6) 25 (28.4) 0.5310
Positive 36 (77.0) 11 (23.0)
Adjuvant hormonal therapy
No 36 (66.7) 18 (33.3) 0.1527
Yes 63 (77.8) 18 (22.2)
Adjuvant chemotherapy
No 22 (75.9) 7 (24.1) 0.7282
Yes 77 (72.6) 29 (27.4)
a 11 patients with locoregional recurrence, 15 patients with distant recurrence and 10
patients with both locoregional and distant recurrences.
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135 patients according to the 18-gene scores revealed gradually evolu-
tion of gene expression proﬁling and distinct gene expression patterns
among patients with or without recurrence (locoregional or distant).
There is existence of a gray zone in this heatmap (Fig. 2).
Clinical decisions are intended to be philosophically more conserva-
tive and tend toward over-treating patients. On that basis, the optimal
cutoff score was 44 on the Receiver Operating Characteristic (ROC)
curve. Patients with 18-gene scores of ≧44 are deﬁned as high risk,
and scores of b44 are deﬁned as the low risk group. The overall accuracyTable 2
Cross validation of the datasets between 2006 and 2014: The 30 and 18 GOI partitioning
mastectomy patients into locoregional recurrence (LRR). Deﬁnition of low- and high- risk
groups: each gene gives equal weighting for scoring algorithm.
Dataset Risk group (scores) Patient number LRR# (%) p Value
30 GOI
2006 (N = 94) High risk (≥21) 33 25(75.8) b0.0001
Low risk (b21) 61 2(3.3)
2014 (N = 135) High risk (≥21) 38 20(52.6) b0.0001
Low risk (b21) 97 3(3.1)
18 GOI
2006 (N = 94) High risk (≥14) 23 16(69.6) b0.0001
Low risk (b14) 71 11(15.5)
2014 (N = 135) High risk (≥14) 43 20(46.5) b0.0001
(Cross validation) Low risk (b14) 92 3(3.3)of these predictions is 93%, with an estimated sensitivity of 87% and a
speciﬁcity of 94% (Fig. 3a). The 5-year LRR-free survival rate in patients
with scores of ≥44 and b44 is 30% and 99% (p b 0.0001), respectively
(Fig. 3b). The time to recurrence (locoregional or distant) by the
18-gene score for all 135 patients is plotted in Fig. 3c. Patients with
recurrences usually had scores of more than 40; patients with scores
of b21 usually were disease-free (only one patient developed distant
metastasis).
3.1. Partitioning Patients According to Nodal Status and Breast Cancer
Subtype
According to the lymph node status, the 5-year LRR-free survival
rates in N0 and N1 patients with the scores of ≥44 and b44 were statis-
tically different (51% versus 100%, and 27% versus 100%, p b 0.0001). N2
patients were too small to draw a conclusion (Table 3). Patients, who
were deﬁned by the 18-gene classiﬁer as high risk, also had poor rates
of 5-year distant metastasis-free survival, and overall survival, regard-
less of whether they were node-negative or node-positive. Node nega-
tive patients with scores of b44 were low risk of distant metastasis;
the 5-year metastasis-free survival rate was excellent, at 95%. In
contrast, the high risk N0 patients had a poor 5-year metastasis-free
survival rate of 22% and overall survival rate of 44%. The detailed
information is summarized in Table 3.
As for the breast cancer subtype, the 18-gene classiﬁer also demon-
strated a similar capability of predicting LRR and distant metastasis
regardless of the breast cancer subtype (Table 3). Luminal-like
(hormonal receptor positive and HER2 negative) subtype predicted as
the high risk group had the best LRR-free survival rate of 50% when
compared with those rates of HER2 subtype (0%) and triple negative
breast cancer (14%).
3.2. Cox Proportional Hazards Model in Mastectomy Patients
We also examined whether the 18-gene classiﬁer is an independent
prognostic factor that is related to LRR. Multivariate analyses revealed
that the prognostic relevance of clinical factors is the extent of lymph
node metastasis and ER status with respect to LRR (Table 3). We re-
analyzed the 135patient samples including these clinical factors togeth-
erwith the 18-gene scores. This analysis conﬁrms the signiﬁcance of the
18-gene classiﬁer as an independent factor associated with LRR. With
the incorporation of the 18-gene score in the proportional hazards
analyses, the hazard ratio for LRR is 31.1 (95% conﬁdence interval,
8.3–115.9) in patients with 18-gene score ≥ 44 (Table 4).
3.3. Performance of the 18-Gene Classiﬁer in BCS Patients
We hypothesized that the gene expression proﬁling derived from
mastectomy patients would also be effective for prediction of LRR in
BCS patients. Eighty-seven (87) BCS patients with microarray informa-
tion were available to prove this hypothesis; these patients (82/87,
94%) have had post-operative radiotherapy (Table 5). Clinical character-
istics of BCS patients are shown in Table 5.
Univariate analysis revealed that BCS patients with the 18-gene
scores of ≥44 (HR 5.8, 95% CI 1.3–26.0) and prominent LVI (HR 4.3,
95% CI 1.0–19.3)were at high risk for LRR.Multivariate analysis by step-
wise selection identiﬁed 18-gene classiﬁer was the only risk factor to
predict LRR in BCS and radiotherapy patients (Table 5).
4. Discussion
We have demonstrated that the 18-gene classiﬁer is capable of
partitioning mastectomy patients into more homogeneous risk groups
of LRR with a biologic difference (Table 2). The 18-gene classiﬁer also
independently predicts LRR regardless of lymph node status, breast
cancer subtype and surgical type (Tables 2 and 5). For N0 and N1
Fig. 3. (a) The receiver operating characteristic (ROC) curve constructed from 18-gene
scoring algorithm as a predictor of locoregional recurrence in patients after mastectomy.
The area under the receiver ROC curve: 0.752 ± 0.040 (95% CI: 0.672–0.831)
(p b 0.001). (b) The 5-year locoregional recurrence (LRR) free survival rates in patients
with an 18-gene score of b44 (low risk group) and ≥44 (high risk group). Among the
low risk group, two LRRs occurred after 5 years of follow-up (see Fig. 3c). (c) The
relation between the 18-gene score and time to recurrence. The X axis is the follow-up
interval (month). The Y axis is the 18-gene score. The orange dot ( ) represents disease
free; the light green triangle ( ) represents LRR and distant recurrences simultaneously;
the red square ( ) represents LRR; and the light blue rhombus ( ) represents distant
metastasis.
Table 3
The 18-gene classiﬁer partitioning patients into different risk subgroups according to
lymph node status and breast cancer subtype.
18-gene
score
Patient
#
Five-year
LRR-free survival
rate
Five-year
metastasis-free
survival rate
Five-year
overall survival
rate
N0 patients
Low risk 83 100.0% 95.1% 95.6%
High risk 9 50.8% 22.2% 44.4%
P value b0.0001 b0.0001 b0.0001
N1 patients
Low risk 24 95.2% 76.6% 77.6%
High risk 11 27.3% 22.7% 26.7%
P value b0.0001 0.0014 0.0272
≥N2 patients 8 Too small to be analyzed
Luminal-like subtype
Low risk 55 100% 90.4% 90%
High risk 12 50% 31.3% 57.1%
P value b0.0001 b0.0001 b0.0001
HER2 subtype
Low risk 38 97.4% 94.7% 97.4%
High risk 8 0% 0% 14.6%
P value b0.0001 b0.0001 b0.0001
Triple negative subtype
Low risk 13 100% 92.3% 84.6%
High risk 7 14.3% 14.3% 14.3%
P value b0.0001 0.0007 0.0050
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free survival rates are 95–100%; those with scores of 44 or greater, the
LRR-free survival rates drop to only 27–51% (Table 3). This observation
gives new insight that our gene panel may help patients and clinicians
to make better decisions about PMRT.
Gene expression proﬁles that predict distant metastases in breast
cancer have been reported since 2002 (Glinsky et al., 2004; van 't Veer
et al., 2002; van de Vijver et al., 2002). The current study gives another
example that gene expression proﬁling is capable of estimating the risk
of LRR. This is crucial in clinical practice because high risk LRR requires
post-operative radiotherapy not only to reduce local recurrence, but
also prevent distant metastasis (EBCTCG et al., 2014). The Danish Breast
Cancer Cooperative Group (DBCG) reported a 7-gene proﬁle, which
could divide mastectomy patients into the “high LRR risk” and “low
LRR risk” groups (Tramm et al., 2014). The LRR rate in the “low risk”
group is about 7–8% and the “high risk” group ranges from 50–60%.
Their LRR genes are totally different from ours. The LRR rate in their
“low risk” patients is higher than ours (our data shows b2% at 5 years,
Fig. 3B). This may be related to different treatment years and ethnicity
(Curtis et al., 2008). Others have reported a 12-gene expression assay,
which is useful to predict LRR in ductal carcinoma in situ patients after
a wide excision (Solin et al., 2013). Our work here observes similarTable 4
Multivariate analysis by Cox proportional hazards model for locoregional recurrence in all
mastectomy patients (N = 135).
Variable Hazards ratio (95% conﬁdence interval) p Value
Analysis without 18-gene classiﬁer
ER status Positive 1.0
Negative 3.6 (1.4, 9.4) 0.0089
N stage N0 1.0
N1 14.2 (4.4, 45.3) b0.0001
N2 31.2 (8.8, 110.3) b0.0001
Analysis with 18-gene classiﬁer
ER status Positive 1.0
Negative 2.4 (1.0, 5.8) 0.0597
N stage N0 1.0
N1 5.0 (1.5, 16.4) 0.0088
N2 4.3 (1.1, 16.8) 0.0345
18-gene score b44 1.0
≥44 31.1 (8.3, 115.9) b0.0001
Table 5
Univariate and multivariate analysis of locoregional recurrence (LRR) for breast-conserv-
ing surgery patients (N = 87).
Risk factor Patient# LRR# LRR
rate
Univariate
analysis (95%
conﬁdence interval)
Multivariate
analysis (95%
conﬁdence interval)a
Age
≤40 19 2 10.5 1.4 (0.3–7.1)
N40 68 5 7.4 1.0
T stage
T1 54 2 3.7 1.0
T2 33 5 15.2 4.3 (0.8–22.2)
N stage
N0 56 4 7.1 1.0
N1 21 2 9.5 1.3 (0.2–7.2)
≥N2 10 1 10.0 1.6 (0.2–14.7)
Nuclear grade
III 44 4 9.1 1.4 (0.3–6.4)
I/II 43 3 7.0 1.0
Lymphovascular invasion
Prominent 14 3 21.4 4.3 (1.0–19.3)⁎
Absent/focal 73 4 5.5 1.0
ER status
Negative 25 3 12.0 2.0 (0.5–9.1)
Positive 62 4 6.5 1.0
PR status
Negative 32 3 9.4 1.3 (0.3–5.9)
Positive 55 4 7.3 1.0
HER2 overexpression
Positive 25 2 8.0 1.2 (0.2–6.2)
Negative 62 5 8.1 1.0
Adjuvant H/T
No 26 4 15.4 3.5 (0.8–15.7)
Yes 61 3 4.9 1.0
Adjuvant C/T
No 11 0 0.0 NA
Yes 76 7 9.2
18-gene score
≥44 18 4 22.2 5.8 (1.3–26.0)⁎ 5.8 (1.3–26.0)⁎
b44 69 3 4.4 1.0 1.0
Bold values represents p value b 0.05.
⁎ p b 0.05.
a Stepwise selection for multivariate Cox model.
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can distinguish the LRR low risk group from the LRR high risk after
breast cancer surgery.
The 18 genes are associated with the oncogenic process, proliferation
invasion, inﬂammation, cell–cell interaction, apoptosis and metabolism
(Ellis et al., 1995; Irie et al., 1998; Jin et al., 1997; Kamps et al., 1990;
Nomura et al., 1993; Pines and Hunter, 1989; Semba et al., 1986). The ex-
pression of one or more of BLM, TCF3, PIM1, DDX39, BUB1B, STIL, TPX2,
CCNB1, MMP15, CCR1, NFATC2IP, OBSL1, C16ORF7, and DTX2 indicates
an increased likelihood of breast cancer LRR. On the contrary, the expres-
sion of one or more of RCHY1, PTI1, ENSA, and TRPV6 indicates a de-
creased likelihood of breast cancer LRR (Fig. 2). Compare to the
Oncotype Dx, our gene set has one overlapping gene (CCNB1) and anoth-
er gene in the same family (MMP11 Oncotype Dx and MMP15 for ours)
(Soonmyung Paik et al., 2004). CCNB1 is also an important gene in
PAM50 gene set (Dowsett et al., 2013). The details of 18-gene function
are listed in Table S4.
The 18-gene signatures are mainly for N0 and N1 mastectomy pa-
tients. In literature, the risk of LRR inN0 patients is about 2–8%,whereas
our gene classiﬁer identiﬁes about 10% of N0 patients to be high risk
(Clarke et al., 2005; EBCTCG et al., 2014). Among them, 49% had LRR
and 78% developed distant metastases (Table 2). This is extremelyimportant because by current practice guidelines these patients would
not be given PMRT; in fact, they are high risk of both locoregional and
distant recurrences. Similarly, the risk of LRR in N1 patients is about
20% in literature, whereas our gene classiﬁer identiﬁes 31% of N1 pa-
tients to be at high risk, whose risk of LRR is 73% (Table 2) (EBCTCG
et al., 2014). Although our patient number is relatively small, it provides
good opportunity for better cancer care. As mentioned in our previous
study, optimal sensitivity and speciﬁcity of the gene expression proﬁles
are desirable in order to avoid having “truly” high risk patients undergo
suboptimal treatment and “truly” low risk patients undergo over-
treatment (Cheng et al., 2006b). Achieving such a goal appears possible
according to the current study (Fig. 3).
Decisions regarding whether to assign N1 mastectomy patients to
adjuvant radiotherapy, which are made based on clinical parameters,
results in the over-treatment of 80% of patients (EBCTCG et al., 2014).
The prevalence of PMRT for N1 patients has increased gradually from
32% in 2007 to 46% in 2012 by SEER registry data since the recommen-
dation of NCCN guidelines (Frasier et al., 2015). The lack of biological
markers may partially explain the low guideline adherence rate. How-
ever, PMRT applied to patients reduces not only LRR, but also improves
their overall survival odds by preventing distantmetastases (Poortmans
et al., 2015; Ragaz et al., 2005). It is essential to identify truly “high risk”
patients for the prevention of LRR and distant metastasis. The present
study reveals that N0 and N1 patients can be sorted into more homoge-
neous subgroups by the 18-gene classiﬁer (Table 2). Both MA20 and
EORTC 22922 studies have shown marginal effects on overall survival
by regional node irradiation (Poortmans et al., 2015; Whelan et al.,
2015). The 18-gene panel is potentially useful in identiﬁcation of the
truly “high risk” patients who would beneﬁt most from PMRT/regional
node irradiation, and it would omit radiotherapy in the low risk patients.
The 18-gene classiﬁer is in many ways similar to the Oncotype Dx
21-gene panel, except in supporting the decision of adjuvant radiother-
apy. The cost-effectiveness analysis suggests that the 21-gene panel is
cost saving in comparison with conventional decision-making process-
es (Holt et al., 2013; Kondo et al., 2011; Vataire et al., 2012). It is possible
that our test will provide an opportunity to optimize treatment
prescription by avoiding unnecessary radiotherapy and by prescribing
radiotherapy to women who would not have received it based on the
standard decision criteria (Table 3).
PMRT is given to the patient one fraction per day and 5 fractions per
week. It usually takes 5 to 6 weeks to complete a course of treatment.
The treatment places heavy burdens on not just the patients, but also
their families and the society; inconveniences that include the daily
commutes for treatment, absence from theirworkplaces, the rearrange-
ments ofmanpower due to the employee having to take leave, addition-
al ﬁnancial expenses… etc. Our test may facilitate the right treatment
for the right patient and would consequently alleviate the burdens on
the patients, their families, and society.
The 18-gene classiﬁer could distinguish the truly “high risk” breast
cancer patients for post-operative radiotherapy. It contributes to the
current call for precision medicine in oncology. Our gene expression
proﬁling is an example of such effort for radiation oncologists to move
toward greater precision in their practice ofmedicine. Our 18-gene clas-
siﬁer is useful for determining whether radiotherapy should or should
not be considered for N0-N1 patients with breast cancer (Table 4).
Our present study is an initial exploration for genomic risk factors
and therefore did not reach the level of randomization. The potential
weakness lies in the fact that the proportion of N1 patients in this
135-patient series is fewer due to the tendency for N1 patients to be
given PMRT between 2005 and now due to the encouragement by the
EORTCG to irradiate N1 patients (Clarke et al., 2005). Our series thus
contains larger N0 population and may not have included large enough
N1 population.
Also, this study lacks certain parameters required of a validation
study for biomarkers. In principle, the requirement should include:
(1) Technical validity: the measurement is reproducible; (2) Clinical
80 S.H. Cheng et al. / EBioMedicine 5 (2016) 74–81validity: the assay identiﬁes a biologic difference; and (3) Clinical utili-
ty: the assay leads to a new clinical decision (Novelli et al., 2008;
Teutsch et al., 2009). According to this deﬁnition, this study has con-
ﬁrmed that themultigene panel developed since 2006 could identify bi-
ologically different subgroups and lead to a better clinical decision about
post-mastectomy radiotherapy. This study has not totally met the ﬁrst
criteria because of different study platforms (Affymetrix U95 versus
Affymetrix U133 Plus 2.0). A validation study using the dataset from
the phase III study, such as MA.20 with pre-deﬁned criteria and assay
is necessary to conﬁrm the true value of 18-gene classiﬁer in the deci-
sion of adjuvant radiotherapy.
In summary, the 18-gene classiﬁer independently estimates the like-
lihood of LRR in breast cancer patients after mastectomy. As we have
mentioned the 18-gene classiﬁer is capable of partitioning N0 and N1
patients into more homogeneous subgroups. A larger validation study
of these patients by using formalin-ﬁxed parafﬁn embedded tissues or
fresh frozen tissues is underway to conﬁrm the broader value of this
genomic predictor and its value in improving health care via more indi-
vidualized prediction of treatment outcomes.
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